|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||239.05 - 241.86|
|52-week range||210.28 - 276.69|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||19.87|
|Earnings date||26-Jul-2021 - 30-Jul-2021|
|Forward dividend & yield||7.04 (2.92%)|
|1y target est||254.96|
Julie Hyman and Anjalee Khemlani breakdown what the FDA’s approval of Biogen’s Alzheimer’s drug will mean for the pharmaceutical industry as Biogen experienced a surge in shares and releases the cost of the treatment.
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.